Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 6/2014

Open Access 01-06-2014 | Original Article

Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Authors: Dimitri Bellevre, Cécile Blanc Fournier, Odile Switsers, Audrey Emmanuelle Dugué, Christelle Levy, Djelila Allouache, Cédric Desmonts, Hubert Crouet, Jean-Marc Guilloit, Jean-Michel Grellard, Nicolas Aide

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2014

Login to get access

Abstract

Purpose

Point spread function (PSF) reconstruction improves spatial resolution throughout the entire field of view of a PET system and can detect smaller metastatic deposits than conventional algorithms such as OSEM. We assessed the impact of PSF reconstruction on quantitative values and diagnostic accuracy for axillary staging of breast cancer patients, compared with an OSEM reconstruction, with emphasis on the size of nodal metastases.

Methods

This was a prospective study in a single referral centre in which 50 patients underwent an 18F-FDG PET examination before axillary lymph node dissection. PET data were reconstructed with an OSEM algorithm and PSF reconstruction, analysed blindly and validated by a pathologist who measured the largest nodal metastasis per axilla. This size was used to evaluate PET diagnostic performance.

Results

On pathology, 34 patients (68 %) had nodal involvement. Overall, the median size of the largest nodal metastasis per axilla was 7 mm (range 0.5 – 40 mm). PSF reconstruction detected more involved nodes than OSEM reconstruction (p = 0.003). The mean PSF to OSEM SUVmax ratio was 1.66 (95 % CI 1.01 – 2.32). The sensitivities of PSF and OSEM reconstructions were, respectively, 96 % and 92 % in patients with a largest nodal metastasis of >7 mm, 60 % and 40 % in patients with a largest nodal metastasis of ≤7 mm, and 92 % and 69 % in patients with a primary tumour ≤30 mm. Biggerstaff graphical comparison showed that globally PSF reconstruction was superior to OSEM reconstruction. The median sizes of the largest nodal metastasis in patients with nodal involvement not detected by either PSF or OSEM reconstruction, detected by PSF but not by OSEM reconstruction and detected by both reconstructions were 3, 6 and 16 mm (p = 0.0064) respectively. In patients with nodal involvement detected by PSF reconstruction but not by OSEM reconstruction, the smallest detectable metastasis was 1.8 mm.

Conclusion

As a result of better activity recovery, PET with PSF reconstruction performed better than PET with OSEM reconstruction in detecting nodal metastases ≤7 mm. However, its sensitivity is still insufficient for it to replace surgical approaches for axillary staging. PET with PSF reconstruction could be used to perform sentinel node biopsy more safely in patients with a primary tumour ≤30 mm and with unremarkable PET results in the axilla.
Appendix
Available only for authorised users
Literature
1.
go back to reference Groheux D, Espie M, Giacchetti S, Hindie E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388–405.PubMedCrossRef Groheux D, Espie M, Giacchetti S, Hindie E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388–405.PubMedCrossRef
2.
go back to reference Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.PubMedCrossRef Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.PubMedCrossRef
3.
go back to reference Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:32–40.PubMedCrossRef Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:32–40.PubMedCrossRef
4.
go back to reference Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2010;37:1069–76.PubMedCentralPubMedCrossRef Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2010;37:1069–76.PubMedCentralPubMedCrossRef
5.
go back to reference Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–27.PubMedCrossRef Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–27.PubMedCrossRef
6.
go back to reference Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2011;37:187–98.PubMedCrossRef Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2011;37:187–98.PubMedCrossRef
7.
go back to reference Andersen FL, Klausen TL, Loft A, Beyer T, Holm S. Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol. 2013;82:862–9.PubMedCrossRef Andersen FL, Klausen TL, Loft A, Beyer T, Holm S. Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol. 2013;82:862–9.PubMedCrossRef
8.
go back to reference Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6.PubMedCrossRef Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6.PubMedCrossRef
9.
go back to reference Aide N, Desmonts C, Beauregard JM, Beyer T, Kinross K, Roselt P, et al. High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. Eur J Nucl Med Mol Imaging. 2010;37:991–1001.PubMedCrossRef Aide N, Desmonts C, Beauregard JM, Beyer T, Kinross K, Roselt P, et al. High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. Eur J Nucl Med Mol Imaging. 2010;37:991–1001.PubMedCrossRef
10.
11.
go back to reference Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCentralPubMedCrossRef Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCentralPubMedCrossRef
12.
go back to reference Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2005;46:2083–91.PubMed Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2005;46:2083–91.PubMed
13.
go back to reference Black WC, Armstrong P. Communicating the significance of radiologic test results: the likelihood ratio. AJR Am J Roentgenol. 1986;147:1313–8.PubMedCrossRef Black WC, Armstrong P. Communicating the significance of radiologic test results: the likelihood ratio. AJR Am J Roentgenol. 1986;147:1313–8.PubMedCrossRef
14.
go back to reference Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365:1500–5.PubMedCrossRef Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365:1500–5.PubMedCrossRef
15.
go back to reference Groheux D, Hindie E, Rubello D, Espie M, Baillet G, Giacchetti S, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging. 2009;36:1539–42.PubMedCrossRef Groheux D, Hindie E, Rubello D, Espie M, Baillet G, Giacchetti S, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging. 2009;36:1539–42.PubMedCrossRef
16.
go back to reference Biggerstaff BJ. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med. 2000;19:649–63.PubMedCrossRef Biggerstaff BJ. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med. 2000;19:649–63.PubMedCrossRef
17.
go back to reference Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375–89.PubMedCrossRef Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375–89.PubMedCrossRef
18.
go back to reference Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PETCT Discovery-690. Med Phys. 2011;38:5394–411.PubMedCrossRef Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PETCT Discovery-690. Med Phys. 2011;38:5394–411.PubMedCrossRef
19.
go back to reference Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol. 2012;19:1808–17.PubMedCrossRef Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol. 2012;19:1808–17.PubMedCrossRef
20.
go back to reference Kuru B, Camlibel M, Dinc S, Gulcelik MA, Alagol H. Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy. Eur J Surg Oncol. 2003;29:839–44.PubMedCrossRef Kuru B, Camlibel M, Dinc S, Gulcelik MA, Alagol H. Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy. Eur J Surg Oncol. 2003;29:839–44.PubMedCrossRef
21.
go back to reference Aukema TS, Straver ME, Valdes Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896–7.PubMedCrossRef Aukema TS, Straver ME, Valdes Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896–7.PubMedCrossRef
22.
go back to reference Chua S, Groves AM. Pretreatment PET in breast cancer: is there a role? Eur J Nucl Med Mol Imaging. 2012;39:1827–9.PubMedCrossRef Chua S, Groves AM. Pretreatment PET in breast cancer: is there a role? Eur J Nucl Med Mol Imaging. 2012;39:1827–9.PubMedCrossRef
23.
go back to reference Gilardi L, De Cicco C, Paganelli G. Preoperative FDG PET/CT in breast cancer patients: where are we going? Eur J Nucl Med Mol Imaging. 2012;39:1667–9.PubMedCrossRef Gilardi L, De Cicco C, Paganelli G. Preoperative FDG PET/CT in breast cancer patients: where are we going? Eur J Nucl Med Mol Imaging. 2012;39:1667–9.PubMedCrossRef
24.
go back to reference Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22.PubMedCrossRef Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22.PubMedCrossRef
25.
go back to reference Akamatsu G, Mitsumoto K, Ishikawa K, Taniguchi T, Ohya N, Baba S, et al. Benefits of point-spread function and time of flight for PET/CT image quality in relation to the body mass index and injected dose. Clin Nucl Med. 2013;38:407–12.PubMedCrossRef Akamatsu G, Mitsumoto K, Ishikawa K, Taniguchi T, Ohya N, Baba S, et al. Benefits of point-spread function and time of flight for PET/CT image quality in relation to the body mass index and injected dose. Clin Nucl Med. 2013;38:407–12.PubMedCrossRef
26.
go back to reference Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52 Suppl 2:93S–100S.PubMedCrossRef Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52 Suppl 2:93S–100S.PubMedCrossRef
27.
go back to reference Boellaard R. Optimisation and harmonisation: two sides of the same coin? Eur J Nucl Med Mol Imaging. 2013;40:982–4.PubMedCrossRef Boellaard R. Optimisation and harmonisation: two sides of the same coin? Eur J Nucl Med Mol Imaging. 2013;40:982–4.PubMedCrossRef
28.
go back to reference Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507–15.PubMedCrossRef Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507–15.PubMedCrossRef
29.
go back to reference Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.PubMedCrossRef Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.PubMedCrossRef
31.
go back to reference Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.PubMedCentralPubMedCrossRef Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.PubMedCentralPubMedCrossRef
Metadata
Title
Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?
Authors
Dimitri Bellevre
Cécile Blanc Fournier
Odile Switsers
Audrey Emmanuelle Dugué
Christelle Levy
Djelila Allouache
Cédric Desmonts
Hubert Crouet
Jean-Marc Guilloit
Jean-Michel Grellard
Nicolas Aide
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2689-7

Other articles of this Issue 6/2014

European Journal of Nuclear Medicine and Molecular Imaging 6/2014 Go to the issue